输血依赖型地中海贫血患者启动罗特西普后出现急性脾肿大、溶血和血小板减少:一例病例报告
输血依赖型地中海贫血患者需终身红细胞输注,罗特西普可减少部分输血依赖型β-地中海贫血患者的输血需求。本文报告一例输血依赖型地中海贫血患者启动罗特西普后出现严重脾肿大、溶血和血小板减少,需停药。监管批准后已有报告发现髓外造血风险并更新安全性标签。
要点
- 罗特西普可减少部分输血依赖型β-地中海贫血患者的输血需求。
- 监管批准后已有报告发现罗特西普相关髓外造血风险并更新安全性标签。
- 本例输血依赖型地中海贫血患者启动罗特西普后出现严重脾肿大、溶血和血小板减少,需停药。
核心结论
- 本文报告一例输血依赖型地中海贫血患者启动罗特西普后出现严重脾肿大、溶血和血小板减少,需停药。
研究设计与样本
- 病例报告。
主要发现
- 一例输血依赖型地中海贫血患者启动罗特西普后出现严重脾肿大、溶血和血小板减少,需停药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with transfusion-dependent thalassaemia (TDT) require chronic, life-sustaining red blood cell transfusions, which contribute to iron overload and associated morbidity and mortality. Luspatercept, an inhibitor of the transforming growth factor-beta pathway, decreases transfusion requirements in a subset of transfusion-dependent β-thalassaemia patients and is increasingly prescribed in clinical practice. Subsequent to regulatory approvals, several reports have identified the risk of extra-medullary haematopoiesis, which resulted in updated safety labelling. In this report, we present a case of a patient with TDT who developed severe splenomegaly, haemolysis and thrombocytopenia necessitating treatment discontinuation.
引用
- Zaidel B, Garland S, Merkeley H, et al. Acute splenomegaly, haemolysis, and thrombocytopenia following luspatercept initiation in a patient with transfusion-dependent thalassaemia: A case report. Br J Haematol. 2025. PMID: 40307204. doi:10.1111/bjh.20131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。